Search research articles
Contact Us
Filters
Showing results (161-170 of 274) with videos related to
Page
of 28
Sort By:
Clinical Genitourinary Cancer
|
February 15, 2008
The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial
Karen G Chee, Jeff Longmate, David I Quinn, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 22, 2016
Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma
Hiroyuki Cho, Seiji Matsumoto, Yoshiko Fujita, et al.
Cancer Chemotherapy and Pharmacology
|
March 26, 2005
A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109
Peter J Van Veldhuizen, James R Faulkner, Primo N Lara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 29, 2011
Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer
Primo N Lara, Jean-Yves Douillard, Kazuhiko Nakagawa, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 26, 2009
The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells
Phillip R Purnell, Philip C Mack, Clifford G Tepper, et al.
JAMA Network Open
|
August 1, 2023
Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG 1216 Phase 3 Trial
Nicolas Sayegh, Umang Swami, Yeonjung Jo, et al.
Cancer
|
August 10, 2019
Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy
Afsaneh Barzi, Primo N Lara, Denice Tsao-Wei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2009
Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317
Michael S Gordon, Michael Hussey, Raymond B Nagle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 10, 2008
Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003
Philip C Mack, Mary W Redman, Kari Chansky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 1, 2007
Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group
Christopher W Ryan, Bryan H Goldman, Primo N Lara, et al.
Page
of 28
Search research articles
Search
Showing results (161-170 of 274) with videos related to
Sort By:
Page
of 28
Clinical Genitourinary Cancer
|
February 15, 2008
The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial
Karen G Chee, Jeff Longmate, David I Quinn, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 22, 2016
Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma
Hiroyuki Cho, Seiji Matsumoto, Yoshiko Fujita, et al.
Cancer Chemotherapy and Pharmacology
|
March 26, 2005
A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109
Peter J Van Veldhuizen, James R Faulkner, Primo N Lara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 29, 2011
Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer
Primo N Lara, Jean-Yves Douillard, Kazuhiko Nakagawa, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 26, 2009
The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells
Phillip R Purnell, Philip C Mack, Clifford G Tepper, et al.
JAMA Network Open
|
August 1, 2023
Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG 1216 Phase 3 Trial
Nicolas Sayegh, Umang Swami, Yeonjung Jo, et al.
Cancer
|
August 10, 2019
Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy
Afsaneh Barzi, Primo N Lara, Denice Tsao-Wei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2009
Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317
Michael S Gordon, Michael Hussey, Raymond B Nagle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 10, 2008
Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003
Philip C Mack, Mary W Redman, Kari Chansky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 1, 2007
Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group
Christopher W Ryan, Bryan H Goldman, Primo N Lara, et al.
Page
of 28